The Corindus team is back to our office in Waltham after another successful Transcatheter Cardiovascular Therapeutics (TCT) conference under our belt! TCT is one of the most important conferences of the year in Interventional Cardiology and attracted key opinion leaders and physicians from across the world and US specifically.
Two groundbreaking documentaries illustrated the need for a better solution for protection in the cath lab in particular given the increasing number of complex PCI cases:
- “Invisible Impact: The Risk of Ionizing Radiation on Cath Lab Staff” tells the story of distinguished endovascular Interventionalist and Arizona Heart Institute Founder Dr. Edward (Ted) Diethrich and his personal health crises related to chronic, low-level exposure to ionizing radiation.
- “Robotics Reducing the Burden of a Life in the Cath Lab” features interventional cardiologist Dr. Vijay Iyer and the serious spinal injuries he suffered as a result of wearing heavy lead apparel to protect himself from the harmful effects of radiation exposure required for his procedures in the cath lab. Dr. Iyer is a committed CorPath user and uses Robotic PCI routinely to reduce his personal burden.
During the meeting, CorPath was highlighted in several featured talks on robotic PCI from some of the industry’s most notable physicians. Dr. Giora Weisz discussed the integration of new technologies to improve cath lab care and paint the vision of the cath lab and the critical role robotics will play. Dr. Ehtisham Mahmud presented data on the applicability of robotic PCI in complex cases and highlighted his experience using robotic PCI in high risk PCI.
This year, six abstract posters and presentations featured CorPath on subjects including feasibility of radial-access robotic PCI; Longitudinal Geographic Miss (LGM) in robotic-assisted versus manual PCI; and the RAPID (Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease) Study*.
We hosted our third users group meeting, with TCT 2015 marking the largest users meeting held to date. The event included peer-to-peer facilitated discussions of best practices and robotic “tips & tricks.” Among the topics and findings discussed were:
- Application of robotics for complex and high-risk indicated patients
- Discussions of learning curve for robotic PCI
- Integration of fellowship programs for robotic PCI at teaching hospitals with the CorPath System and the potential to broaden the teaching
The highlight of our booth was the CorPath Vascular Robotic System, which attendees were able to test drive in a simulated complex PCI case.
In the end, TCT 2015 provided yet another great opportunity for the Corindus team, CorPath users and booth visitors to discuss the need to work together to champion the role of robotic PCI in working to improve patient care and creating a safe cath lab for all.
*This information concerns a use that has not been cleared by the FDA. The CorPath 200 System has not been evaluated in Peripheral Vascular Interventions by the FDA. Corindus Vascular Robotics, Inc. sponsored the RAPID Trial.